What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Tuftsin-derived anxiolytic neuropeptide
Overview
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Russia, built by appending a C-terminal Pro-Gly-Pro stabiliser to the immunoactive tuftsin fragment (Thr-Lys-Pro-Arg). The same Pro-Gly-Pro tail that gives Semax its extended half-life slows enzymatic degradation here too, turning a rapidly-cleaved tetrapeptide into a peptide with a usable in-vivo window. It is studied as a non-sedating anxiolytic and neuromodulator, with research lines spanning GABAergic and serotonergic signalling, BDNF expression, and enkephalin-degradation kinetics. Every Vialdyne lot of Selank acetate is released at ≥99.0% HPLC main-peak purity, with a batch COA bundling RP-HPLC peak integration, peptide-content assay, water (Karl Fischer), acetic-acid counter-ion, residual solvents, and endotoxin. LC-MS/MS sequence confirmation and the raw chromatogram are documented add-ons on the same lot for labs qualifying a new reference source.
Applications & buyer fit
Cognitive and neuropeptide buyers are predominantly research labs running in vivo rodent studies. The dominant administration route in the literature is intranasal, these peptides are not meaningfully blood-brain-barrier permeable when delivered systemically. For in vivo workflows, endotoxin and microbial-limit testing is recommended at the COA stage so the bioassay readout is not confounded by contamination unrelated to the test article.
Sourced for
Buyer fit
Documentation that ships
Procurement note: For in vivo workflows, endotoxin and microbial-limit testing on the specific lot is recommended at the COA stage.
Primary buyer fit: academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for Selank, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →Selank
VD260428-SK10174 · 99.37%
VerifiedRequest full COA →Selank
VD260428-SK5173 · 99.05%
Regulatory note
Research-use-only reference material. Selank is registered as a medicine in the Russian Federation but is not approved by the FDA or EMA; not for human or veterinary use. Buyers are responsible for verifying regulatory status in the destination market.
Selected literature
Frequently asked questions
Selank is the synthetic peptide Thr-Lys-Pro-Arg-Pro-Gly-Pro: the natural immunopeptide tuftsin (Thr-Lys-Pro-Arg) extended with a C-terminal Pro-Gly-Pro stabiliser. That Pro-Gly-Pro tail is the same degradation-slowing motif used in Semax (an ACTH(4-10) analogue), which is why the two Russian-developed neuropeptides are catalogued together. Tuftsin alone is cleaved within minutes; the Pro-Gly-Pro extension gives Selank a longer enzymatic window while shifting the pharmacology toward anxiolytic and neuromodulatory research endpoints.
Each released lot carries a batch-specific COA: appearance, identification, HPLC purity (released ≥99.0% main-peak), peptide-content assay, related substances, water by Karl Fischer, acetic-acid counter-ion, residual solvents to ICH Q3C, bacterial endotoxin (LAL), and sterility. LC-MS/MS sequence confirmation and the raw RP-HPLC chromatogram are available on request for method-development and reference-standard files.
